# Spero Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2025

- Company: [Spero Therapeutics, Inc.](/companies/spro.md) (CIK 1701108)
- Form: 10-K
- Filed: 2026-03-26
- Accepted by EDGAR: Mar 26, 2026, 16:05 ET
- Period: 2025-12-31
- Accession: 0001193125-26-126192
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1701108/000119312526126192/spro-20251231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1701108/000119312526126192/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2025-01-01 to 2025-12-31 | $12.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months, 2025-01-01 to 2025-12-31 | $38.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2025-01-01 to 2025-12-31 | $6.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months, 2025-01-01 to 2025-12-31 | $261.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2025-01-01 to 2025-12-31 | $8.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2025-01-01 to 2025-12-31 | $0.15 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2025-01-01 to 2025-12-31 | $0.15 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2025-01-01 to 2025-12-31 | 59,039,225 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2025-01-01 to 2025-12-31 | −$12.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2025-12-31 | $40.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-12-31 | $67.3m | us-gaap:AssetsCurrent |
| Total assets | at 2025-12-31 | $68.9m | us-gaap:Assets |
| Current liabilities | at 2025-12-31 | $8.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-12-31 | $9.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2025-12-31 | $59.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1701108/000119312526126192/spro-20251231.htm

Filed Mar 26, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-126192. Last ingested by Listed: Nov 13, 2026, 16:27 ET. No prices; not investment advice.
